<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Track</th>
<th>Presentation Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>10-Oct</td>
<td>6:00-7:00 AM</td>
<td>Cancer Diagnostics</td>
<td>Precise Detection of T-Cell Receptors Using RNAseq With Unique Molecular Indexing</td>
<td>Samuel Rulli, PhD&lt;br&gt;Senior Global Product Manager, RNA Profiling, QIAGEN</td>
</tr>
<tr>
<td>10-Oct</td>
<td>6:00-7:00 AM</td>
<td>Cancer Therapeutics and Vaccines</td>
<td>The Role of Vaccination for the Treatment and Prevention of Breast and Ovarian Cancers</td>
<td>Keith Knutson, PhD&lt;br&gt;Professor of Immunology, Mayo Clinic</td>
</tr>
<tr>
<td>10-Oct</td>
<td>7:30-8:30 AM</td>
<td>Cancer Diagnostics</td>
<td>Keynote Presentation: Proteogenomics and Cancer Biology: Insights for Prognosis and Therapy</td>
<td>Karin Rodland, PhD&lt;br&gt;Director and Professor, Biological Sciences Division, Pacific Northwest National Laboratory</td>
</tr>
<tr>
<td>10-Oct</td>
<td>9:00-10:00 AM</td>
<td>Cancer Diagnostics</td>
<td>Understanding Cancer Through Whole-Genome Screening</td>
<td>Andrew Ravanelli, PhD&lt;br&gt;Senior R&amp;D Scientist, Genome and Epigenome Editing, MilliporeSigma</td>
</tr>
<tr>
<td>10-Oct</td>
<td>9:00-10:00 AM</td>
<td>Cancer Therapeutics and Vaccines</td>
<td>Using Radiotherapy, Tumor-Reactive mAb and IL2 to Engage Innate and Adaptive Antitumor Immunity</td>
<td>Paul Sondel, MD, PhD&lt;br&gt;Professor of Pediatrics, Department of Human Oncology &amp; Genetics, University of Wisconsin-Madison</td>
</tr>
<tr>
<td>10-Oct</td>
<td>10:30-11:30 AM</td>
<td>Cancer Epigenetics and Natural History</td>
<td>Metabolic Networks in the Tumor Microenvironment</td>
<td>Costas A. Lyssiotis, PhD&lt;br&gt;Assistant Professor, Department of Molecular and Integrative Physiology, Department of Internal Medicine, Division of Gastroenterology and Hepatology, Rogel Cancer Center, University of Michigan</td>
</tr>
<tr>
<td>10-Oct</td>
<td>10:30-11:30 AM</td>
<td>Cancer Microbiome</td>
<td>Microbiome Signatures in Gynecologic Cancers</td>
<td>Marina Walther-Antonio, PhD&lt;br&gt;Associate Consultant, Department of Surgery &amp; Department of Obstetrics &amp; Gynecology, Assistant Professor, Microbiome Program, Center for Individualized Medicine, Mayo Clinic</td>
</tr>
<tr>
<td>10-Oct</td>
<td>12:00-1:00 PM</td>
<td>Cancer Therapeutics and Vaccines</td>
<td>Integrative Cancer Immunology and Novel Concepts of Cancer Evolution</td>
<td>Jerome Galon, PhD&lt;br&gt;Research Director, French Institute of Health and Medical Research</td>
</tr>
<tr>
<td>10-Oct</td>
<td>12:00-1:00 PM</td>
<td>Cancer Diagnostics</td>
<td>Sample to Insight: Everything You Need to Know About RNA Sequencing</td>
<td>Jonathan Shaffer, MBA, PhD&lt;br&gt;Associate Director, NGS Assay Technologies, QIAGEN</td>
</tr>
<tr>
<td>10-Oct</td>
<td>1:30-2:30 PM</td>
<td>Cancer Diagnostics</td>
<td>Discovery of Biomarkers Predictive of Anticancer Drug Response in Preclinical Settings</td>
<td>Benjamin Haibe-Kains, PhD&lt;br&gt;Assistant Professor, Princess Margaret Cancer Center, University of Toronto</td>
</tr>
<tr>
<td>11-Oct</td>
<td>6:00-7:00 AM</td>
<td>Cancer Diagnostics</td>
<td>Revealing the Hidden Landscape of Structural Variants in Cancer Genomes</td>
<td>Jonas Korfch, PhD&lt;br&gt;Chief Scientific Officer, Pacific Biosciences</td>
</tr>
<tr>
<td>Date</td>
<td>Time</td>
<td>Section</td>
<td>Title</td>
<td>Presenter</td>
</tr>
<tr>
<td>--------</td>
<td>------------</td>
<td>----------------------------------------------</td>
<td>-------------------------------------------------------------------------------------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>11-Oct</td>
<td>7:30-8:30 AM</td>
<td>Cancer Epigenetics and Natural History</td>
<td>Keynote Presentation: In Advanced Cancers Curative Therapies Must Target All Cancer Cells</td>
<td>Krastan Blagoev, PhD</td>
</tr>
<tr>
<td>11-Oct</td>
<td>9:00-10:00 AM</td>
<td>Cancer Epigenetics and Natural History</td>
<td>Destabilization and Degradation of MYC: More Ways Than One</td>
<td>Jason De Melo, PhD</td>
</tr>
<tr>
<td>11-Oct</td>
<td>9:00-10:00 AM</td>
<td>Cancer Diagnostics</td>
<td>Discovering Cellular Mechanisms and Markers in Anti-PD1 Non-Responders Through Ingenuity Pathway Analysis and Oncoland</td>
<td>Devendra Mistry, PhD</td>
</tr>
<tr>
<td>11-Oct</td>
<td>10:30-11:30 AM</td>
<td>Cancer Theraputics and Vaccines</td>
<td>Drug Targeting for Inflammatory Breast Cancer</td>
<td>Kevin Williams, PhD</td>
</tr>
<tr>
<td>11-Oct</td>
<td>10:30-11:30 AM</td>
<td>Cancer Diagnostics</td>
<td>Validating and Publishing with Antibodies-How to Avoid Reviewer’s Challenges</td>
<td>Chandra Mohan, PhD</td>
</tr>
<tr>
<td>11-Oct</td>
<td>12:00-1:00 PM</td>
<td>Cancer Theraputics and Vaccines</td>
<td>Aurora Kinase A Drives The Evolution of Resistance to Third Generation EGFR Inhibitors in Lung Cancer</td>
<td>Khyati Shah, PhD</td>
</tr>
<tr>
<td>11-Oct</td>
<td>12:00-1:00 PM</td>
<td>Cancer Epigenetics and Natural History</td>
<td>Lung Cancer Evolution and Immune Escape</td>
<td>Nicholas McGranahan, PhD</td>
</tr>
<tr>
<td>11-Oct</td>
<td>1:30-2:30 PM</td>
<td>Cancer Theraputics and Vaccines</td>
<td>Breast Cancer as a Global Disease: Are We Up to The Challenge?</td>
<td>Benjamin Anderson, MD</td>
</tr>
<tr>
<td>11-Oct</td>
<td>1:30-2:30 PM</td>
<td>Cancer Epigenetics and Natural History</td>
<td>Exploiting Cis-Regulatory Enhancers as Therapeutic Targets in Cancer</td>
<td>Martin Hirst, PhD</td>
</tr>
</tbody>
</table>